Figure 1.

Study flow chart and preservation of lung histopathology in LCOs

(A) Study workflow. See also Figure S1 and Tables S1–S3.

(B) Bright-field images of LCOs (left column), H&E staining of advanced lung cancer-derived LCOs (middle column), and the primary tumor malignant effusions (right column), including the pericardial effusion, pleural effusion (PE), and ascitic effusion (AE). Scale bars, 100 μm.

(C) IHC staining of the adenocarcinoma-derived LCOs as well as the original tissue with classic subtype markers TTF-1 (left column), CK7 (middle column), and Napsin A (right column). Scale bar, 50 μm.

(D) IHC staining of CK5/6, P40, and P63 in squamous cell carcinoma. Scale bar for the tissue, 50 μm. Scale bar for the LCO, 20 μm.

(E) IHC staining of TTF-1, Syn, CgA, and CD56 markers of small cell lung cancer. Scale bar, 50 μm.